Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne

Reuters

2025/06/09

Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader $(KOL)$ event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465156-en) on June 09, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542386405"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542386405\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542386405?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542386405","market":"us","top_or_hot":-1,"title":"Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&amp;A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465156-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-09 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&amp;A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465156-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL6mMWyx:1","article_id":"2542386405","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542386405","pubTimestamp":1749466857,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader  event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase  inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4139":"生物科技","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SGMT":"Sagimet Biosciences Inc."},"translate_title":"Sagimet Biosciences宣布Denifanstat治疗中度至重度痤疮的3期试验结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SGMT":0.9},"content_text":"Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne\n    \n\nSagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader $(KOL)$ event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465156-en) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}